Oliver Van Oekelen, MD, PhD, discusses how S100A8/A9 in promotes T-cell exhaustion and limits responses to bispecific antibody therapy in multiple myeloma.
Oliver Van Oekelen, MD, PhD
Advertisement
Oliver Van Oekelen, MD, PhD is a bioinformatics-trained MD, PhD, working as an Internal Medicine Resident at the Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel hospital in New York City.
Articles by Oliver Van Oekelen, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
5